Experience with piroxicam in general practice: results of a German multicenter study on 18,888 patients.
18,888 patients with chronic or extra-articular rheumatic diseases were treated for an average period of 36.1 or 26.9 days with the new non-steroidal anti-rheumatic agent piroxicam. In particular, piroxicam had a positive effect in terms of providing relief from pain. Side effects were relatively rare and seldom required discontinuation of treatment. In about 75% of the patients the maintenance dose was 20 mg piroxicam in a single daily dose. No influence on the laboratory values or accompanying diseases were observed.
D000893:Anti-Inflammatory Agents / Q000627:therapeutic use*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy*; D005194:Family Practice; D006801:Humans; D005082:Physical Exertion; D010894:Piroxicam; D013843:Thiazines / Q000009:adverse effects / Q000627:therapeutic use*; D013997:Time Factors
D000893:Anti-Inflammatory Agents; D013843:Thiazines; D010894:Piroxicam